Drug and Alcohol Dependence 2014;145:121-126. [doi: 10.1016/j.drugalcdep.2014.10.002]
R. Kathryn McHugh, PhD (McLean Hospital, NEC Node), Garrett M. Fitzmaurice, ScD (McLean Hospital, NEC Node), Kathleen M. Carroll, PhD (Yale University, NEC Node), Margaret L. Griffin, PhD (McLean Hospital, NEC Node), Kevin P. Hill, MD, MPH (McLean Hospital, NEC Node), Ajay D. Wasan, MD, MSc (Harvard Medical School), Roger D. Weiss, MD (McLean Hospital, NEC Node).
Craving is viewed as a core feature of substance use disorders and has been shown to predict future drug use, particularly over the short term. Accordingly, craving is often assessed in treatment settings as a marker of risk for subsequent drug use. The identification of the briefest measure that maintains predictive validity is of particular value for both clinical and research settings to minimize assessment burden while maintaining utility for the prediction of use. Data from a National Drug Abuse Treatment Clinical Trials Network multi-site clinical trial of treatment for prescription opioid dependence (CTN-0030) were examined to evaluate whether a brief, 3-item craving scale, the Opioid Craving Scale, administered each week predicted urine-confirmed self-report of prescription opioid use in the subsequent week. Logistic regression models examining the association between craving and presence or absence of opioid use in the following week were conducted, controlling for opioid use in the previous week, treatment condition, and lifetime history of heroin use. Greater craving was associated with higher odds of prescription opioid use in the following week. For each one-unit increase on this 10-point scale, the odds of using opioids in the subsequent week was 17% higher. In addition to an item assessing urges, items assessing cue-induced craving and perceived likelihood of relapse in an environment where drugs were previously used contributed uniquely to this association.
Conclusions: A brief measure of prescription opioid craving predicted prescription opioid use among individuals in treatment and demonstrated internal consistency, reliability, and concurrent and predictive validity. This measure offers an efficient strategy to inform the assessment of risk for use in this population and may be a valuable tool in both clinical and research settings. (Article (Peer-Reviewed), PDF, English, 2014)
Keywords: Buprenorphine/Naloxone |
Craving | CTN platform/ancillary study | Opioid dependence | Pharmacological therapy |
Prescription-type opiates | Screening and assessment instruments | Drug and Alcohol Dependence (journal)
Document No: 1105, PMID: 25454409, PMCID: PMC4254575.
Submitted by CTN Dissemination Librarians, 10/21/2014.